Novo Nordisk's adjusted operating profit reached DKK 32,858 million in Q1 2026

⦿ Executive Snapshot

What: Novo Nordisk reported a Q1 2026 adjusted operating profit of DKK 32,858 million, alongside significant sales growth driven by the Wegovy® product line.
Who: Key players include Novo Nordisk, led by CEO Mike Doustdar, and the US regulatory bodies involved in the approval process.
Why it matters: The company's financial performance reflects a strong market position in obesity care, highlighting the impact and potential of GLP-1 therapies on chronic disease management.

Q1 2026 reported sales increased by 32% at CER, positively impacted by a provision reversal related to the 340B Drug Pricing Program in the US.
Q1 2026 adjusted sales decreased by 4% at CER, driven by lower realised prices, partly offset by GLP-1 volume growth.
Wegovy® sales reached DKK 2,256 million in Q1 2026, marking the strongest-ever GLP-1 volume launch in the US with total prescriptions exceeding 2 million since launch.

The launch of the Wegovy® pill in January 2026 signifies a pivotal moment in obesity treatment, establishing Novo Nordisk’s leadership in the GLP-1 market.
The company’s recent approvals for new products within the obesity and diabetes segments reflect a broader trend towards innovative therapeutic solutions for chronic diseases.

Immediate market consequences include increased competition for obesity treatments and potential shifts in market share among pharmaceutical companies focused on chronic disease.
Long-term implications involve the establishment of Wegovy® as a benchmark product, influencing future research and development in peptide-based therapies.

Regulatory challenges may arise as Novo Nordisk seeks to expand Wegovy® into international markets outside the US, especially concerning pending approvals.
Competition from other pharmaceutical companies developing similar obesity and diabetes treatments could impact Novo Nordisk's market share and pricing strategy.

The anticipated launches of Wegovy® outside the US in the second half of 2026 will be critical in assessing the product's global impact and market penetration.
Future developments in the approval of additional products in the pipeline, such as Wegovy® HD and Awiqli®, will signal the company’s ability to maintain its growth trajectory and innovate in chronic disease management.